Drugmakers Have Tough Task In Quest For AIA Exemption

By Ryan Davis (September 11, 2015, 4:28 PM EDT) -- Pharmaceutical companies may be able to make a case that their patents should not be subject to America Invents Act reviews since they can already be challenged through the Hatch-Waxman process, attorneys say, but the industry's bid to get Congress to exempt drug patents from AIA proceedings could face long odds.

Leaders of branded drug companies on Tuesday reiterated their call for legislation that would prohibit AIA reviews of pharmaceutical patents, in part in response to challenges to numerous drug patents by hedge fund manager Kyle Bass. The companies argue new drug patents are expensive and difficult to obtain and should...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!